A diverse scala of refined molecular techniques, developed during early positional cloning and the Human Genome project, has caused a rapid increase of our insight into the cause of genetic diseases. Nowadays, from cytogenetic rearrangements to point mutations can be readily detected by a variety of techniques. This not only has broadened our understanding, but has also enormously assisted in providing rapid and specific diagnosis, hence reducing uncertainty and improving the choices for those concerned with genetic disease in their family. While initially restricted to the DNA-level, diagnostic technology has gradually been tailored to suit the specifics of the diseases in question, incorporating RNA and protein analysis. The latest development in the analysis of genetic disease is reviewed. (Keio J Med 43 (3): 211-213, December 1994) 
A diverse scala of refined molecular techniques has been developed since the early successful attempts at positional cloning of disease genes and the subsequent upscaling of gene technology in the framework of the Human Genome project. This has exponentially increased our insights into the causes of genetic disease. Initially the route from linkage to gene has been viewed by sceptics as a 'sound but dull' approach following a fixed, run-of-the-mill procedure. However, the discovery of most major genetic disease genes has in practice turned into a fascinating tale of original strategies, resourceful tinkering, fruitful collaboration, challenging competition and unexpected findings.
Linkage analysis has been extended to linkage disequi librium (allelic association), sib pair and homozygosity by-descent studies. The power of these approaches was greatly augmented by the ever-densening array of highly informative PCR-markers. The strength of disease gene studies in population isolates is increasingly being em ployed to highlight common disease genes, much like how focussing on hereditary cancer genes has yielded many insights into their much more frequent stochastic counterparts.
Novel mutation mechanisms were found, the prime example being the dynamic mutations of instable trinu cleotide repeats underlying Fragile X syndrome,1 myotonic dystrophy on chromosome 19,2.3 X-linked spinobulbar muscular atrophy,4 Huntington disease on chromosome 45 and spinocerebellar ataxia on chromosome 6,6 with other late-onset neurodegenerative diseases very likely following suit. A second novel finding concerns the recurrent, specific duplication of 1.5 Mb of DNA on chromosome 17p for Charcot-Marie-Tooth disease 1A 7,8 and its deletion counterpart in hereditary pressure -sensitive neuropathy.9 In the familiar cancer field, no tably hereditary nonpolyposis coli, yet another novel mutational mechanism has recently surfaced in the form of defective mismatch repair genes, which have a specific ' mutator' effect on dinucleotide, trinucleotide and poss ibly other simple sequence repeats (SSR) throughout the genome.10,11 These mutator genes greatly increase over all SSR instability and are thought to act in cascade, by causing stochastic mutations in other genes involved in cellular regulation, which contain such repeats. Recombinational mutation mechanisms are associated with arrays of repetitive DNA in facioscapulohumeral muscular dystrophy near the chromosome 4q telomere12,13 and possibly also in recessive spinal muscular atrophy types I, II and III on proximal chromosome 5q. In contrast, more random chromosomal deletion and dupli cation events are causing X-linked Duchenne and Becker muscular dystrophy 14,15 and chromosome 17 linked neurofibromatosis. 16 In these case of Duchenne these events show, despite their apparent stochastic size and inconspicuous flanking sequences, a remarkable non -random distribution across the 2.5Mb gene, which is as yet not understood but may be a consequence of chromo somal structure.
Typically, the disease genes where the mutational mechanism did not involve chromosomal rearrangements have arrived later on the scene, and sometimes still due to a rare case of chromosomal abnormality. Several of the major diseases, such as cystic fibrosis (chromosome 7q) and familiar cancer syndromes like polyposis coli (5q) and Li-Fraumeini syndrome (17p) appear to be mostly caused by point mutattons or deletions of a few bp.
Not only have these advances enormouuumously broadened our understanding of genetic disease, but they have also greatly assisted in providing rapid and specific diagnosis, hence reducing uncertainty and improving the choices for those concerned with such disease in their family. Nowadays, from cytogenetic rearrangements to point mutations can be readily detected by a variety of tech niques and ultimately determined by sequence analysis. While diagnostic technology initially was mainly restric ted to the DNA-level, it has gradually been tailored to suit the specifics of the diseases in question, incorporating RNA and protein analysis in a mixture of molecular, cellular and developmental biology. Some of the develop ments in the analysis of genetic disease will be reviewed.
Rapid and sensitive point mutation detection, includ ing denaturing gradient gel electrophoresis (DGGE), single-strand conformation polymorphism (SSCP) and the protein truncation test (PTT).17,18 The latter is a test newly developed in our laboratory, which selectively detects the entire scala of early termination mutations in any genetic disease by a standardized technique using in vitro transcription-translation.
Early protein diagnosis in fetal material and in cul tured cells after in vitro differentiation. An example will be given of a diagnostic case, where dystrophin diagnosis in a terminated pregnancy finally allowed the rigorous determination of the mother's non-carriership. 19 Second, for future application in prenatal diagnosis and carrier -determination we are establishing a system for detecting muscle proteins in chorionic-villus cells and primary fibroblasts, after using myoD gene sequences to bring about the myogenic differentiation.20 After several days, successful differentiation can be monitored by the ap pearance of desmin expression, which is otherwise absent from fibroblasts and CVS cells. Subsequently, after a few more days, the cells are studied for their expression of dystrophin. At present the development of the system is still in its infancy, but further increases in efficiency should yield a system in which a variety of muscle specific gene defects could be diagnosed at the protein level, starting out from much more easily obtainable tissue sources than a muscle biopsy. Finally, some of the recent advances will be shown in the field of cytogenetic analysis. Fluorescence in situ hybridization (FISH) studies have brought about great progress in the detection of chromosomal abnormalities and the identification of the underlying genetic mechan isms.21,22 On one hand, metaphase FISH analysis has been greatly facilitated by the use of painting techniques and the availability of many chromosome and gene-specific probes.23 This has allowed widespread introduction of the technique to resolve myriad diagnostic questions. On the other hand, novel methods of "FiberFISH" (extended single DNA-fiber FISH analysis), notably the 'DNA -halo'24 and 'Dirvish'25 techniques, are generating an unprecedented resolution, essentially allowing one to visualise the map at about a one-kb resolution directly through the light microscope. This is especially invaluable in the determination of order and distance of genes, or sequences separated by only a few tens or hundred kb of uncloned DNA. Further, it permits detailed inspection of the boundaries of regions where rearrangements have occurred, for micro-irregularities. Finally, FiberFISH is also an excellent tool to determine the map and compo sition of YAC clones.
